Fig. 6: Comp34 targets and inhibits mTOR through cellular mechanisms different from rapamycin. | Cell Death & Disease

Fig. 6: Comp34 targets and inhibits mTOR through cellular mechanisms different from rapamycin.

From: Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA

Fig. 6

a MDA-MB-231 and rapamycin-resistant MDA-MB-231 cell lines (RR1, RR2) were treated with the indicated concentrations of rapamycin for 48 h. MTS cell proliferation assay was performed to determine the cell growth inhibition. Each dot and error bar on the curves represents mean ± SD (n = 6). b RR1 cells were treated with Comp34 or rapamycin for 48 h. The cell growth inhibition was determined. Each dot and error bar on the curves represents mean ± SD (n = 6). c AKT/mTOR signaling was assessed by WB using the indicated protein-specific antibodies. d RR1 cells were treated with the indicated concentrations of Comp34 for 24 h. AKT/mTOR signaling was evaluated by WB. e MDA-MB-231 cells were treated with 100 nM rapamycin for 24 h. RT-PCR was performed to measure NUDT3-AS4 level. f RR1 cells were treated with or without 100 nM Comp34 for 24 h. RT-PCR was performed to measure NUDT3-AS4, miR-99s levels, and AKT1/mTOR mRNA levels. **P < 0.01 versus control.

Back to article page